NeoStem has rebounded this week after a Seeking Alpha blog post suggested its AMR-001 stem cell treatment for cardiovascular disease was unlikely to work.
http://www.forbes.com/sites/johnfarrell/2013/09/27/neostem-unfazed-by-hiccup-over-its-amr-001-cardiovascular-stem-cell-treatment/
http://www.forbes.com/sites/johnfarrell/2013/09/27/neostem-unfazed-by-hiccup-over-its-amr-001-cardiovascular-stem-cell-treatment/
No comments:
Post a Comment